Price$2.45+0.02 (+0.82%)
01:30 PM07:45 PM
News · 26 weeks47-64%
2026-01-182026-07-12
Mix2990d
- Other11(38%)
- SEC Filings8(28%)
- Insider7(24%)
- Earnings2(7%)
- Leadership1(3%)
Latest news
25 items- PRCo-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific OfficerSALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO"). Dr. Lindsey brings more than 20 years' experience in molecular diagnostics. He holds a PhD in Genetics & Molecular Biology from Emory University and an MBA from Georgia State University. Over his career, Dr. Lindsey has led assay development and R&D teams that produced more than a dozen FDA 510(k)
- SECSEC Form PRE 14A filed by Co-Diagnostics Inc.PRE 14A - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, ThailandInvited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partnerWorkshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnosticsSALT LAKE CITY, July 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the United Nations Office for Project Services' (UNOPS) Global Implementation Workshop on Near Point of Care (NP
- PRCo-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care TestMore than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runsAnalytical data to support concurrent 510(k) submission with CLIA Waiver by Application for point-of-care settings, with submission targeted for Q3 2026SALT LAKE CITY, July 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of clinical and analytical performance studies for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® inst
- PRCo-Diagnostics Vector Smart® Division Expands Footprint to 21 StatesExpansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its mosquito abatement district ("MAD") customer base for the Vector Smart® line of products and services have grown to include MADs in 21 states, with four new full laboratory installs added in June alone. The announcement coincides with Co-Dx hosting a webinar for prospective MAD customers in recognition
- PRCo-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing LineVisit has included tour of Utah headquarters and automated manufacturing facilities ahead of planned technology transfer SALT LAKE CITY, June 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that a delegation from CoMira Diagnostics ("CoMira"), the Company's joint venture with partners in the Kingdom of Saudi Arabia ("KSA"), visited Co-Diagnostics' Salt Lake City headquarters ahead of a planned technology transfer to CoMira. The visit included a tour of the Company's facilities and unveiling a future automated manufacturing
- PRCo-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor AgreementLongstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu of molecular diagnostics products across a key Latin American marketSALT LAKE CITY, June 11, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into an exclusive distribution agreement with its longstanding partner in Mexico for the Co-Dx™ PCR point-of-care platform*, including the PCR Pro® instrument and associated test kits, advancing the Company's strategy to expand its commercialization network and footprin
- SECSEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.SCHEDULE 13G - Co-Diagnostics, Inc. (0001692415) (Subject)
- PRCo-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform CapabilitiesDual-assay strategy designed to support outbreak response and surveillance efforts in affected regionsPotential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of-care platform capabilitiesSALT LAKE CITY, June 2, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics Pvt. Ltd. ("CoSara" or the "JV"). The program includes development of both a pan-Ebola assay designed to rapidly detect multiple ebolavirus sp
- SECSEC Form EFFECT filed by Co-Diagnostics Inc.EFFECT - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECSEC Form S-3 filed by Co-Diagnostics Inc.S-3 - Co-Diagnostics, Inc. (0001692415) (Filer)
- INSIDERChief Executive Officer Egan Dwight H was granted 4,584 shares and returned $8,279 worth of shares to the company (1,633 units at $5.07), increasing direct ownership by 12% to 27,893 units (SEC Form 4) (withholding tax)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERChief Financial Officer Brown Brian Lee was granted 3,750 shares and returned $6,844 worth of shares to the company (1,350 units at $5.07), increasing direct ownership by 12% to 22,379 units (SEC Form 4) to cover taxes4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERPresident Abbott Richard David was granted 1,890 shares and returned $3,448 worth of shares to the company (680 units at $5.07), increasing direct ownership by 55% to 3,417 units (SEC Form 4) (withholding obligation)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERDirector Murphy Edward L. was granted 1,695 shares, increasing direct ownership by 18% to 11,084 units (SEC Form 4)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERDirector Serbin Richard S was granted 1,695 shares, increasing direct ownership by 19% to 10,751 units (SEC Form 4)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERDirector Durenard Eugene was granted 1,695 shares, increasing direct ownership by 19% to 10,668 units (SEC Form 4)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERDirector Nelson James B was granted 1,695 shares, increasing direct ownership by 19% to 10,668 units (SEC Form 4)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- PRCo-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSaraJoint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globallySALT LAKE CITY, May 26, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has advanced the PCR assay development strategy for the Bundibugyo virus ("BDBV") currently causing an outbreak of Ebola disease in the Democratic Republic of the Congo ("DRC") and Uganda, with the support of CoSara Diagnostics Pvt. Ltd. ("CoSara" or the "JV"), the Indian joint venture between Co-Dx and Amb
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesSALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into a securities purchase agreement with certain institutional investors to sell an aggregate of 1,647,447 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 3,294,894 shares of common stock, in a private placement priced at-the-market under Nasdaq rules (the "Offering"). The combined effective offering price for each share of common stock (or pre-funded warrant in-li
- PRCo-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak AlertRecent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platformFollows outbreak of Ebola and WHO emergency declaration, and enhanced CDC traveler screening measuresSALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has completed the assay development strategy for the Bundibugyo virus ("BDBV") currently causing an outbreak of Ebola disease in the Democratic Republic of the Congo and Uganda.
- SECSEC Form EFFECT filed by Co-Diagnostics Inc.EFFECT - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECSEC Form 10-Q filed by Co-Diagnostics Inc.10-Q - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
CODX FAQ
7 questionsWhat does Co-Diagnostics Inc. do?
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant...Where does CODX stock trade?
Co-Diagnostics Inc. (CODX) is listed on NASDAQ.What sector and industry is CODX in?
Co-Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Co-Diagnostics Inc. go public?
Co-Diagnostics Inc. (CODX) completed its IPO in 2026.What are analysts saying about CODX?
Co-Diagnostics Inc. has had 3 recent analyst actions on file. The most recent action was from Sidoti: Neutral with a $500.00 price target on 2022-08-12. Recent price targets range from $500.00 to $1500.00.What companies are similar to CODX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare CODX side-by-side with any of them on Quantisnow.How can I track CODX on Quantisnow?
Quantisnow aggregates Co-Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CODX to receive live email and push alerts on every new disclosure.